Light Mode
$3.26 ↓ -0.07 (-2.10%) Trading Down from the previous close of $3.33, $0.04 below the day’s high of $3.30
+2.87 (+620.31%) / 6M
Momentum, market sentiment, and recent alerts
IMMP reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +73.4%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.